Team
Katja Stout, MBiochem (Oxon), MBA
Founder and Managing Partner
London
Katja is a communications strategist and entrepreneur with over twenty five years of international experience in the life sciences and pharmaceutical industry. A serial entrepreneur, she has founded two communications consultancies.
In 2021 Katja supported Vaccitech’s $160 million series B financing followed quickly by its $150 million Nasdaq IPO. Scius has worked with a range of international life sciences clients including Anocca, BC Platforms, Epitopea, Microbiotica, and TILT Biotherapeutics to support financings and business development deals.
Subsequently Katja spent four years at AstraZeneca firstly as Director of Partnering Communications in the business development team. She later became Vice President of Corporate Affairs, Global Product and Portfolio Strategy (GPPS) and was a member of the GPPS leadership team. In this role she was responsible for leading the communications for all of AstraZeneca’s global product brands and launching the new GPPS function internally.
Prior to founding Northbank, Katja held in-house roles at leading investment firms including SV Life Sciences, International BioTechnology Trust and Merlin Biosciences. She also worked at life sciences investor relations firm, Russell-Welsh (now GCI Healthcare), based in San Francisco, California. Earlier in her career, Katja was Head of communications and IR at Genset SA (now part of Merck Serono), a pioneer in personalised healthcare, listed on Nasdaq and the Nouveau Marche and based in Paris.
Katja has a Masters degree in Biochemistry from Oxford University and an MBA from Imperial College London.
